Abstract
Enzalutamide (Xtandi—Astellas, Medivation), an androgen receptor inhibitor previously known as MDV3100, has been approved for men with late-stage (metastatic) castration-resistant prostate cancer previously treated with docetaxel. The drug was reviewed under FDA's priority review program and received approval 3 months ahead of schedule.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call